NASDAQ: RGNXRegenxbio Inc Stock
$9.61+0.20 (+2.13%)
Updated Apr 30, 2025
RGNX Price
$9.61
Fair Value Price
N/A
Market Cap
$481.33M
52 Week Low
$5.04
52 Week High
$17.52
P/E
-2.09x
P/B
1.85x
P/S
4.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$83.33M
Earnings
-$227.10M
Gross Margin
59.7%
Operating Margin
-257.35%
Profit Margin
-272.5%
Debt to Equity
0.8
Operating Cash Flow
-$173M
Beta
1.33
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RGNX Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RGNX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RGNX
Ranked#96 of 462
Ranked#96 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important RGNX news, forecast changes, insider trades & much more!
RGNX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RGNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RGNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RGNX is good value based on its book value relative to its share price (1.85x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
RGNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RGNX due diligence checks available for Premium users.
Valuation
RGNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.09x
Industry
-162.28x
Market
29.18x
RGNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.85x
Industry
4.45x
RGNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RGNX's financial health
Profit margin
Revenue
$21.2M
Net Income
-$51.2M
Profit Margin
-241.3%
RGNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RGNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$466.0M
Liabilities
$206.3M
Debt to equity
0.8
RGNX's short-term assets ($278.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGNX's short-term assets ($278.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RGNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.6M
Investing
$40.3M
Financing
-$7.7M
RGNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RGNX vs Biotech Stocks
Regenxbio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.